Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway

Acta Histochemica

Volumn 114, Issue 7, 2012, Pages 641-646

  Uluer, Elgin Turkoz ^a   Aydemir, Isil ^b   Inan, Sevinc ^a   Ozbilgin, Kemal ^a   Vatansever, Hafize Seda ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

5 FU; Gemcitabine; JAK; MCF 7; STAT

Indexed keywords

FLUOROURACIL; GEMCITABINE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LOCALIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROTEIN LOCALIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84863482330     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.11.010     Document Type: Article

References (47)

1. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 1999, 17:138-146.
2. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000, 19:2607-2611.
3. Ali S., El-Rayes B.F., Aranha O., Sarkar F.H., Philip P.A. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res Treat 2005, 90:25-31.
4. Alvarez J.V., Febbo P.G., Ramaswamy S., Loda M., Richardson A., Frank D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005, 65:5054-5062.
5. Bromberg J.F., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
7. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003, 197:157-168.
8. Clarkson R.W.E., Boland M.P., Kritikou E.A., Lee J.M., Freeman T.C., Tiffen P.G., et al. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006, 20:675-685.
9. Clevenger C.V., Furth P.A., Hankinson S.E., Schuler L.A. The role of prolactin in mammary carcinoma. Endocrine Rev 2003, 24:1-27.
10. Clevenger C.V. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004, 165:1449-1460.
11. Coletta R.D., Jedlicka P., Gutierrez-Hartmann A., Ford H.L. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004, 9:39-53.
12. Cotarla I., Ren S., Zhang Y., Gehan E., Singh B., Furth P.A. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004, 108:665-671.
13. Dearolf C.R. JAKs and STATs in invertebrate model organisms. Cell Mol Life Sci 1999, 55:1578-1584.
14. Desantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 10.3322/caac.20134.
15. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
16. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002, 29:9-16.
17. Heinemann V. Gemcitabine in metastatic breast cancer. Exp Rev Anticancer Ther 2005, 5:429-443.
18. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556.
19. Hsieh F.C., Cheng G., Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005, 335:292-299.
20. Hussain S.A., James N.D. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003, 4:489-497.
21. Hynes N.E., Watson C.J. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol 2010, 2:a003186.
22. Iavnilovitch E., Groner B., Barash I. Overexpression and forced activation of Stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 2002, 1:32-47.
23. Iavnilovitch E., Cardiff R.D., Groner B., Barash I. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004, 112:607-619.
24. Jordheim L.P., Guittet O., Lepoivre M., Galmarini C.M., Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005, 4:1268-1276.
25. Kisseleva T., Bhattacharya S., Braunstein J., Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002, 285:1-24.
26. Laird A.D., Li G., Moss K.G., Blake R.A., Broome M.A., Cherrington J.M., et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Therap 2003, 2:461-469.
27. Levy D.E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell Mol Life Sci 1999, 55:1559-1567.
28. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
29. Ling X., Arlinghaus R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005, 65:2532-2536.
30. Mui A.L. The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci 1999, 55:1547-1558.
31. Nevalainen M.T., Xie J., Torhorst J., Bubendorf L., Haas P., Kononen J., et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004, 22:2053-2060.
32. O'Shea J.J. Targeting the JAK/STAT pathway for immunosuppression. Ann Rheum Dis 2004, 63:67-71.
33. Philp J.A., Burdon T.G., Watson C.J. Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett 1996, 396:77-80.
34. Ramalingam S., Belani C.P. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004, 31:68-74.
35. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J Cell Sci 2004, 117:1281-1283.
36. Ren S., Cai H.R., Li M., Furth P.A. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002, 21:4335-4339.
37. Sasi W., Jiang W.G., Sharma A., Mokbel K. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 2010, 10:178.
38. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017-8023.
39. Smithgall T.E., Briggs S.D., Schreiner S., Lerner E.C., Cheng H., Wilson M.B. Control of myeloid differentiation and survival by Stats. Oncogene 2000, 19:2612-2618.
40. Vaclavicek A., Bermejo J.L., Schmutzler R.K., Sutter C., Wappenschmidt B., Meindl A., et al. Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer 2007, 14:267-277.
41. Verma A., Kambhampati S., Parmar S., Platanias L.C. Jak family of kinases in cancer. Cancer Metastasis Rev 2003, 22:423-434.
42. Walker S.R., Nelson E.A., Zou L., Chaudhury M., Signoretti S., Richardson A., et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009, 7:966-976.
43. Watson C.J. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2001, 6:115-127.
44. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947.
45. Ying M., Li D., Yang L., Wang M., Wang N., Chen Y., et al. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol 2010, 136:1617-1626.
46. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
47. Zoli W., Ulivi P., Tesei A., Fabbri F., Rosetti M., Maltoni R., et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res 2005, 7:681-689.